---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-004451"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:35:16.706594+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience reports 52-week weight loss of 22.3% for nimacimab+semaglutide combo; no plateau observed

## Summary
- Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
- Weight regain at 13-week off-therapy follow-up was 17.8% for combo vs 37.3% for semaglutide alone, a >50% reduction in rebound.
- No serious adverse events or AESIs reported during 52-week extension; safety profile maintained.
- Full topline Phase 2a extension data expected in Q3 2026; cash runway into Q4 2026.

## SEC filing metadata
- accession: 0001628280-26-004451
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/0001628280-26-004451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-004451
- JSON: https://secwatch.observer/filing/0001628280-26-004451.json
- Plain text: https://secwatch.observer/filing/0001628280-26-004451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.